coronary heart disease
Conditions
Interventions
Experimental group:In addition to standard treatment for coronary heart disease, finelidone was given: 20mg orally once daily for 16 weeks.
Control group:standard treatment for coronary heart disease, including antiplatelet drugs and statins
Sponsors
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age > = 18 years old and 50% of major coronary arteries. 3eGFR>=60 mL/min/1.73 m²(CKD-EPI). 4. UACR>=30 mg/g and < 300 mg/g. 5. Voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Suffering from dilated cardiomyopathy, chemotherapy-induced cardiomyopathy, hereditary hypertrophic cardiomyopathy, and infiltrative cardiomyopathy. 2. History of viral myocarditis and perinatal cardiomyopathy; Has a history of moderate or higher valvular disease. 3. At the same time, take RASi and Chinese patent medicines with proteinuria-lowering effect (Tripterygium wilfordii, Huang Kui, Bailing, Jin Shuibao, etc.). 4. Combined with diabetes mellitus (T1D, T2D, or HbA1c>=6.5%), hypertension, renal artery stenosis. 5. Suffering from rheumatic system diseases (currently using glucocorticoids or anti-rheumatic drugs). 6. Patients with malignant tumors. 7. History of drug or alcohol abuse in the past 12 months. 8. Vulnerable groups, including people with mental illness, cognitive impairment, critically ill patients, female subjects who are pregnant, lactating or have a positive pregnancy test, etc. 9. Other conditions that the investigator considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in UACR from baseline at 16 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| The magnitude of changes in eGFR, an indicator of renal function;Cardio-renal complex endpoints: renal failure, nephro-related death, cardiovascular death, hospitalization for heart failure; | — |
Countries
China
Contacts
Public ContactZhang Wenbin
No. 3 Qingchun East Road, Hangzhou City, Zhejiang Province
Outcome results
None listed